Curated News
By: NewsRamp Editorial Staff
November 24, 2025
GeoVax CEO to Present Corporate Update at NobleCon21 Investor Conference
TLDR
- GeoVax's CEO presentation at NobleCon21 offers investors early insights into vaccine advancements and oncology therapies for potential market advantage.
- GeoVax CEO David Dodd will present a corporate update on December 3, 2025 at 3:00 pm ET in Boca Raton, with webcast availability following the event.
- GeoVax's vaccine development for immunocompromised patients and cancer therapies represents progress toward better healthcare outcomes and disease prevention worldwide.
- GeoVax is advancing directly to Phase 3 trials for its Mpox vaccine and developing novel oncolytic therapies for head and neck cancers.
Impact - Why it Matters
This presentation provides crucial insights into GeoVax's advancing clinical pipeline, particularly their next-generation COVID-19 vaccine for immunocompromised patients and novel cancer immunotherapies. For investors, it represents an opportunity to understand the company's growth trajectory and potential market impact. For the medical community and patients, GeoVax's work addresses critical gaps in current vaccine efficacy for vulnerable populations and advances innovative cancer treatments. The company's progress in developing targeted therapies for conditions where current options remain limited could significantly improve patient outcomes and expand treatment possibilities in infectious diseases and oncology.
Summary
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company specializing in human vaccines and cancer immunotherapies, has announced that its Chairman and CEO David Dodd will present at NobleCon21 - the Noble Capital Markets Twenty-First Annual Emerging Growth Equity Conference. The presentation, scheduled for December 3, 2025, at 3:00 pm ET at Florida Atlantic University's Executive Education Complex in Boca Raton, Florida, will provide a comprehensive corporate update on GeoVax's progress and future direction. This prestigious emerging growth equity conference brings together promising companies with potential investors, making it a significant platform for GeoVax to showcase its innovative pipeline to the financial community.
The company is extending a special invitation to interested investors and guests, offering discounted registration through their designated link where attendees can register here using the discount code GOVXNOBLECON. For those unable to attend in person, a high-definition video webcast will be available the following day through Noble Capital Markets' comprehensive conference website at www.nobleconference.com and on Channelchek, the investor portal created by Noble. The webcast will remain archived for 90 days post-event, ensuring broad accessibility. Additionally, senior GeoVax management will conduct one-on-one meetings with registered attendees, providing deeper insights into the company's strategic initiatives and clinical advancements.
GeoVax's clinical portfolio represents cutting-edge medical innovation, with their lead COVID-19 vaccine candidate GEO-CM04S1 currently in three Phase 2 trials targeting immunocompromised patients, chronic lymphocytic leukemia patients, and healthy individuals seeking more robust protection. Their oncology program features Gedeptin®, a novel oncolytic solid tumor gene-directed therapy that recently completed Phase 1/2 trials for advanced head and neck cancers. The company is also advancing a vaccine targeting Mpox and smallpox, with recent regulatory guidance allowing progression directly to Phase 3 evaluation. With worldwide rights to their technologies and a strong intellectual property portfolio, GeoVax continues to push boundaries in vaccine development and cancer immunotherapy. For comprehensive updates on their clinical trials and corporate developments, investors and interested parties are encouraged to visit www.geovax.com.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, GeoVax CEO to Present Corporate Update at NobleCon21 Investor Conference
